AzTrials
AzTrials

Central Nervous System InfectionNCT00172393

Long Term Outcomes of EV71 CNS Infection

An observational study of Central Nervous System Infection, run by National Taiwan University Hospital at 1 site in Taiwan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Our study involved 142 children with EV71 CNS infections that included 61 (43%) with viral meningitis, 53 (37%) with severe CNS involvement including encephalitis, polio-like syndrome and encephalomyelitis, and 28 (20%) with cardiopulmonary failure after CNS involvement. Read more about this study

Who is it for?
Ages 1 month to 18 yearsHealthy volunteers can take part
Conditions the study is for
Central Nervous System Infection
How many people
150 participants
Where
1 siteTaiwan
Study dates
Jan 2003to May 2005
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 month to 18 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Who may be able to join

  • Virologically-confirmed EV71 cases with CNS involvement

Who cannot join

  • No evidence of EV71 infection
  • No evidence of CNS involvement

Trial locations and contacts

1 site in 1 country.

Taiwan1 site, 1 recruiting
  • National Taiwan University Hsopital

    Taipei, Taipei, 100

    Luan-Yin Chang, MD, PhD, 886-2-23123456 ext. 3245, ly7077@tpts6.seed.net.tw

    Luan-Yin Chang, MD, PhD

    Recruiting

Other trials in Taiwan

About this study

Official title: Long Term Outcomes of EV71 Central Nervous System Infection

Our study involved 142 children with EV71 CNS infections that included 61 (43%) with viral meningitis, 53 (37%) with severe CNS involvement including encephalitis, polio-like syndrome and encephalomyelitis, and 28 (20%) with cardiopulmonary failure after CNS involvement. These children were subjected to physical and neurological examinations 2.85 (range 1.0-7.39) years after disease onset. Those below the age of 6 years took the Denver developmental screening test, while those 4 years and over took the intelligence quotient (IQ) test.

Read the detailed description

For the purposes of our study we identified all the EV71 pediatric patients at Chang Gung Children's Hospital (CGCH) and at the NTUH between 1998 and 2003. These patients were clinically confirmed to have hand, foot, and mouth disease (HFMD) of herpangina or febrile illness, and a positive laboratory-confirmed EV71 infection. The EV 71 infection was confirmed on the basis of a positive viral isolation of EV71 and/or a positive EV71 IgM and/or a four-fold rise in EV71 neutralizing antibody serotiters between the acute and the convalescent sera.

This study involved 621 EV71 patients in total, 534 of them at the CGCH and 87 of them at the NTUH. Of these, 232 cases (37.4%) had CNS involvement. The clinical severity of the EV71 CNS involvement was classified in terms of the increasing severity of the infection: Group 1: cases with mild CNS involvement i.e. aseptic meningitis; Group 2: cases with severe CNS involvement including encephalitis, polio-like syndrome or encephalomyelitis; and Group 3: cases with cardiopulmonary failure after central nervous system involvement. Patients placed in Group 1, were those experiencing headaches, irritability and CSF pleocytosis (>5x106 leukocytes/L) but no altered level of consciousness or focal signs. Patients placed in Group 2, were encephalitis with an altered level of consciousness plus CSF pleocytosis, poliomyelitis-like syndrome with acute limb weakness, and decreased reflex and muscle strength, and encephalomyelitis with the occurrence of both encephalitis and poliomyelitis-like syndrome. Patients placed in Group 3 were those who had experienced cardiopulmonary failure (defined as a decreased ejection fraction of the left ventricle as assessed by echocardiography with or without pulmonary edema/hemorrhage, necessitating inotropic agent and ventilator support). Patients who experienced cardiopulmonary failure after CNS involvement have been found to have had a sudden onset of cardiopulmonary failure several hours or several days after the manifestations of their EV71 CNS infections.5,16 Of these 232 cases with CNS involvement, 25 (10.8%) patients died of cardiopulmonary failure and brainstem encephalitis during acute illness. 19 of these 25 patients died within 7 days of the onset of acute illness, while 14 (6.0%) patients died due to a deep coma or aspiration pneumonia during the convalescent stage (i.e. more than one month after onset of their disease).

Of the remaining 193 patients with CNS involvement (172 of these at the CGCH and 21 of these at the NTUH), 22 refused to be assessed and 29 could not be located. This means that a total of 142 (73.6%) patients were enrolled in our study and took the assessment between January 2003 and December 2005 after informed consent was obtained from their parents (Figure 1). The clinical severity and the demography of the 142 patients who were assessed and the 51 patients who were not assessed (p=0.22 for clinical severity, p=0.33 for their age of onset, and p=0.35 for genders) were similar. It is therefore clear that the size of the study population involving these 142 patients is representative of the 193 EV71 patients with CNS involvement.

Clinical and neurological outcome and neurodevelopment assessment All the children were physically and neurologically examined by a pediatrician or a pediatric neurologist during an outpatient visit or during their stay at chronic respiratory centers. Their physical handicap or neurological sequelae, the requirement of ventilator support and the need of tube feeding were recorded.

EV71 patients who were younger than 6 years of age during our assessment were tested with the Denver Developmental Screening Test (DDST II). The DDST II has four categories: gross motor, fine motor, language, and personal-social.17 Each test item was scored as either passed or failed. The overall assessment of each child was considered normal when the child passed tasks in 25-75% for his/her age, or delayed when the child failed tasks to the left of his/her age line.

Cognitive function assessment The Wechsler Intelligence Scale for Children-Third Edition (WISC-III, Wechsler, 1991) profile was individually assessed by a child psychologist for all children over four years of age except for 3 of the children who had tracheostomy and could not talk. The WISC-III is a widely used measure of general intelligence for children aged 4-16 years. The WISC-III is composed of 13 subtests to test children's cognitive ability of different dimensions, which are grouped into two scores: the performance IQ score and the verbal IQ score. The Performance IQ score (7 subtests) includes Picture Completion, Block Design, Object Assembly, Picture Arrangement, Coding, Symbol Search and Mazes subtests. The Verbal IQ score (6 subtests) includes Information, Comprehension, Arithmetic, Similarities, Digit Span and Vocabulary subtests.18 Four factorially derived composite subscales have been created: (1) Verbal Comprehension: Information, Similarities, Vocabulary, and Comprehension; (2) Perceptual Organization: Picture Completion, Picture Arrangement, Block Design, and Object Assembly; (3) Freedom From Distractibility: Arithmetic and Digit span; and (4) Process Speed: Coding and Symbol Search. 18 Each of the IQ scores and four composite subscales yield standard scores with a mean of 100 and a standard deviation (S.D.) of 15.

Statistical Analysis Data were analyzed with the SAS Statistical Package (Version 9.1, SAS Institute, Cary, North Carolina). Data are expressed as mean ±S.D., median (range) or number (percentage). The Chi-square test was used for categorical data, and the student t-test and analysis of variance (ANOVA) were used for continuous variables with normal distribution. The Mann-Whitney rank sum test or Kruskal-Wallis test was used for continuous variables without a normal distribution in the univariate analysis. If a significant difference was found with ANOVA, pairwise comparison would be performed with the Scheffe test. Multivariate analysis of variance (MANOVA) was used to identify the most significant factors affecting the cognitive function (IQ and the four composite subscales).. P values less than 0.05 were considered significant.

Keywords
EV71,, CNS,, Outcome,, Neurological,, Psychiatric
Medical subject headings
Central Nervous System Infections, Neurologic Manifestations

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Sep 2005 (estimated)
  2. Study startJan 2003
  3. Study completionMay 2005

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Defined population
Time perspective
Other
Enrolment
150 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00172393
Sponsor's protocol ID
9311700446
Status last verified
Jun 2005
First submitted
12 Sep 2005
Last updated
4 Oct 2006
Results posted
No

Publications

  • Gau SS, Chang LY, Huang LM, Fan TY, Wu YY, Lin TY. Attention-deficit/hyperactivity-related symptoms among children with enterovirus 71 infection of the central nervous system. Pediatrics. 2008 Aug;122(2):e452-8. doi: 10.1542/peds.2007-3799. Epub 2008 Jul 7.

    PubMed 18606624
  • Chang LY, Huang LM, Gau SS, Wu YY, Hsia SH, Fan TY, Lin KL, Huang YC, Lu CY, Lin TY. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med. 2007 Mar 22;356(12):1226-34. doi: 10.1056/NEJMoa065954.

    PubMed 17377160

Questions about this trial

What is this clinical trial studying?

An observational study of Central Nervous System Infection, run by National Taiwan University Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Oct 2006. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Luan-Yin Chang, MD (886-2-23123456 ext. 3245, ly7077@tpts6.seed.net.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00172393, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Oct 2006.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in